Idéal Investisseur
Français English
CAC 40 : Market closed
8 365,01 pts
-0.05%


Last updated : 16/11/2026 - 17h14
🏠 Home   ➤    Stock news

Nanobiotix shares fall 5.5%, among the largest declines in the SBF 120

The Paris-based oncology nanomedicine biotech gives back part of its strong November rebound, in a broadly stable Paris market. The decline comes as management is set to address the financial community in London.


Nanobiotix shares fall 5.5%, among the largest declines in the SBF 120

A decline that places the stock at the bottom of the SBF 120

As the market closes, Nanobiotix shares are down 5.3% at €26.42, while the SBF 120 remains stable (+0.01%).

The stock is among the largest decliners in the index, behind Eramet and Inventiva, and this drop reduces its monthly gain to nearly 34%. It also comes with a move below the MM20 (€27.31), while the MM50 (€26.59) is less than 1% from the price.

The stock remains below its MM200, at €29.79, a gap of 11.3%, which shows that this month's rebound has not yet brought the share price back to its long-term trend. This decline extends the alternation of rising and falling sessions observed since the beginning of the month.

London meetings and cash runway through 2029

Nanobiotix is scheduled to present at the Jefferies and UBS conferences in London on November 16 and 17, according to a press release published on November 9. The company is developing NBTXR3 (JNJ-1900), a radioamplifier used in combination with radiotherapy, in partnership with Johnson & Johnson.

When it published its first-half 2026 financial results on September 24, it reported cash of €110.9 million, sufficient to fund its operations through 2029.

The stock is listed in Paris and as ADSs on the Nasdaq, where the index is down 2.15% this Monday: the Paris shares close their session at 5:30 p.m., before the Nasdaq closes its own session.

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Pharmacie et biotechnologies › Biotechnologies


Context

Period
  • Period: S1 2026
Key reported figures
  • Revenue: 3,6 millions d'euros
  • Quarterly revenue: 3,6 millions d'euros
  • Net income: -34,3 millions d'euros
Guidance from the release
  • « la Société estime qu'elle disposera des liquidités suffisantes pour faire face à ses obligations financières […] pendant au moins les 12 prochains mois […] pas de doute substantiel quant à la capacité de la Société à poursuivre son activité » ; CP du 24/09 : trésorerie de 110,9 M€ « permettront de financer ses opérations jusqu'en 2029 »

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours